Novartis Raises Full-Year Guidance After Core Earnings Exceed Consensus
Novartis reported core earnings ahead of consensus expectations and raised its full-year guidance, J.P. Morgan said. Sales were broadly as expected.
Novartis shares seem likely to outperform after the Swiss drugmaker reported core earnings ahead of consensus expectations and raised its full-year guidance, J.P. Morgan says in a research note. Sales were broadly as expected, but core operating profit and core earnings per share both exceeded cons…